Grant S - Search Results

1

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.

Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. Holkova B, et al. Among authors: grant s. Leuk Lymphoma. 2017 Jun;58(6):1349-1357. doi: 10.1080/10428194.2016.1276287. Epub 2017 Jan 19. Leuk Lymphoma. 2017. PMID: 28103725 Free PMC article. Clinical Trial.

2

Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.

Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR. Grant S, et al. Leukemia. 1992 May;6(5):432-9. Leukemia. 1992. PMID: 1593908

3

Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.

Grant S, Baker M, Bhalla K. Grant S, et al. Leukemia. 1993 Dec;7(12):1933-8. Leukemia. 1993. PMID: 8255091 Clinical Trial.

4

Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.

Bear HD, McFadden AW, Kostuchenko PJ, Lipshy KA, Hamad GG, Turner AJ, Roberts JD, Carr M, Carr S, Grant S. Bear HD, et al. Among authors: grant s. Anticancer Drugs. 1996 May;7(3):299-306. doi: 10.1097/00001813-199605000-00010. Anticancer Drugs. 1996. PMID: 8792004

5

Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. Grant S, et al. Clin Cancer Res. 1998 Mar;4(3):611-8. Clin Cancer Res. 1998. PMID: 9533528 Clinical Trial.

6

Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.

Vrana JA, Wang Z, Rao AS, Tang L, Chen JH, Kramer LB, Grant S. Vrana JA, et al. Among authors: grant s. Leukemia. 1999 Jul;13(7):1046-55. doi: 10.1038/sj.leu.2401454. Leukemia. 1999. PMID: 10400420

7

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.

Wang S, Wang Z, Boise LH, Dent P, Grant S. Wang S, et al. Among authors: grant s. Leukemia. 1999 Oct;13(10):1564-73. doi: 10.1038/sj.leu.2401532. Leukemia. 1999. PMID: 10516758

8

Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.

Poplin E, Roberts J, Tombs M, Grant S, Rubin E. Poplin E, et al. Among authors: grant s. Invest New Drugs. 1999;17(1):57-62. doi: 10.1023/a:1006239200772. Invest New Drugs. 1999. PMID: 10555123 Clinical Trial.

9

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.

Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R. Roberts JD, et al. Among authors: grant s. Cancer Chemother Pharmacol. 2000;45(2):103-10. doi: 10.1007/s002800050017. Cancer Chemother Pharmacol. 2000. PMID: 10663624 Clinical Trial.

10

The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. Cartee L, et al. Among authors: grant s. Cancer Res. 2001 Mar 15;61(6):2583-91. Cancer Res. 2001. PMID: 11289135

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,846 results

Search Page

Filters